Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.320
+0.070 (1.65%)
Aug 17, 2026, 11:02 AM EDT - Market open
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenue of $13.82M in the quarter ending June 30, 2026, with 38.15% growth. This brings the company's revenue in the last twelve months to $54.09M, up 22.56% year-over-year. In the year 2025, Aquestive Therapeutics had annual revenue of $44.55M, down -22.61%.
Revenue (ttm)
$54.09M
Revenue Growth
+22.56%
P/S Ratio
9.86
Revenue / Employee
$367,939
Employees
147
Market Cap
542.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.55M | -13.02M | -22.61% |
| Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
| Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
| Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
| Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
| Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
| Dec 31, 2019 | 52.61M | -14.82M | -21.98% |
| Dec 31, 2018 | 67.43M | 512.00K | 0.77% |
| Dec 31, 2017 | 66.92M | 15.13M | 29.22% |
| Dec 31, 2016 | 51.79M | 49.07M | 1,807.37% |
| Dec 31, 2006 | 2.72M | 592.00K | 27.89% |
| Dec 31, 2005 | 2.12M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 915.45M |
| Evotec SE | 819.47M |
| Pacira BioSciences | 746.16M |
| Amphastar Pharmaceuticals | 730.02M |
| Ironwood Pharmaceuticals | 389.32M |
| Evolus | 316.49M |
| Canopy Growth | 206.77M |
| Kamada | 191.85M |
AQST News
- 5 days ago - Aquestive Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 5 days ago - Aquestive Therapeutics Earnings release: Q2 2026 - Filings
- 5 days ago - Aquestive Therapeutics Quarterly report: Q2 2026 - Filings
- 5 days ago - Aquestive Therapeutics Slides: Q2 2026 - Filings
- 5 days ago - Aquestive Therapeutics reports Q2 EPS (18c), consensus (12c) - TheFly
- 5 days ago - Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $50.51M - TheFly
- 5 days ago - Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film - GlobeNewsWire